Butorphanol as a dental premedication in the mentally retarded

Michael Wong Jann, George Fidone, Michael Gorday, Richard R. Rostedt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Seventy institutionalized severely and profoundly retarded patients were administered intramuscular butorphanol, 1.0 to 4.0 mg, for premedication prior to dental procedures. These patients had been refractory to previous combined chloral hydrate and diphenhydramine treatment. Clinical efficacy was categorized according to the extent that adjunctive restraints were required to accomplish the dental procedure. A total of 151 butorphanol trials were recorded. Butorphanol was observed to be clinically effective in 74.8% of the administrations and sedation was observed in 28.2% of the trials. Dosage titration increased efficacy to 85.0%. Contribution of concurrent central nervous system depressant medication to clinical efficacy and dose requirements lacked statistical significance; however, a strong trend (p = 0.068) was found in the medication-free group with higher dosage. Vomiting (2.6%) was the most frequent adverse effect observed. One patient had marked cardiorespiratory depression that was promptly reversed by intravenous naloxone. Two patients experienced mild hypotensive episodes immediately following injection, but they recovered uneventfully. Butorphanol was shown to be a safe and effective agent for dental premedication in this difficult patient population.

Original languageEnglish
Pages (from-to)403-407
Number of pages5
JournalOral Surgery, Oral Medicine, Oral Pathology
Volume63
Issue number4
DOIs
StatePublished - 1 Jan 1987

Fingerprint

Butorphanol
Premedication
Mentally Disabled Persons
Tooth
Central Nervous System Depressants
Chloral Hydrate
Diphenhydramine
Naloxone
Vomiting
Injections
Population

Cite this

Jann, Michael Wong ; Fidone, George ; Gorday, Michael ; Rostedt, Richard R. / Butorphanol as a dental premedication in the mentally retarded. In: Oral Surgery, Oral Medicine, Oral Pathology. 1987 ; Vol. 63, No. 4. pp. 403-407.
@article{60f6bdd87f214d2ca41e2c05689836a9,
title = "Butorphanol as a dental premedication in the mentally retarded",
abstract = "Seventy institutionalized severely and profoundly retarded patients were administered intramuscular butorphanol, 1.0 to 4.0 mg, for premedication prior to dental procedures. These patients had been refractory to previous combined chloral hydrate and diphenhydramine treatment. Clinical efficacy was categorized according to the extent that adjunctive restraints were required to accomplish the dental procedure. A total of 151 butorphanol trials were recorded. Butorphanol was observed to be clinically effective in 74.8{\%} of the administrations and sedation was observed in 28.2{\%} of the trials. Dosage titration increased efficacy to 85.0{\%}. Contribution of concurrent central nervous system depressant medication to clinical efficacy and dose requirements lacked statistical significance; however, a strong trend (p = 0.068) was found in the medication-free group with higher dosage. Vomiting (2.6{\%}) was the most frequent adverse effect observed. One patient had marked cardiorespiratory depression that was promptly reversed by intravenous naloxone. Two patients experienced mild hypotensive episodes immediately following injection, but they recovered uneventfully. Butorphanol was shown to be a safe and effective agent for dental premedication in this difficult patient population.",
author = "Jann, {Michael Wong} and George Fidone and Michael Gorday and Rostedt, {Richard R.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1016/0030-4220(87)90248-9",
language = "English",
volume = "63",
pages = "403--407",
journal = "Oral Surgery, Oral Medicine, Oral Pathology",
issn = "0030-4220",
publisher = "Mosby-Year Book Inc.",
number = "4",

}

Butorphanol as a dental premedication in the mentally retarded. / Jann, Michael Wong; Fidone, George; Gorday, Michael; Rostedt, Richard R.

In: Oral Surgery, Oral Medicine, Oral Pathology, Vol. 63, No. 4, 01.01.1987, p. 403-407.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Butorphanol as a dental premedication in the mentally retarded

AU - Jann, Michael Wong

AU - Fidone, George

AU - Gorday, Michael

AU - Rostedt, Richard R.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Seventy institutionalized severely and profoundly retarded patients were administered intramuscular butorphanol, 1.0 to 4.0 mg, for premedication prior to dental procedures. These patients had been refractory to previous combined chloral hydrate and diphenhydramine treatment. Clinical efficacy was categorized according to the extent that adjunctive restraints were required to accomplish the dental procedure. A total of 151 butorphanol trials were recorded. Butorphanol was observed to be clinically effective in 74.8% of the administrations and sedation was observed in 28.2% of the trials. Dosage titration increased efficacy to 85.0%. Contribution of concurrent central nervous system depressant medication to clinical efficacy and dose requirements lacked statistical significance; however, a strong trend (p = 0.068) was found in the medication-free group with higher dosage. Vomiting (2.6%) was the most frequent adverse effect observed. One patient had marked cardiorespiratory depression that was promptly reversed by intravenous naloxone. Two patients experienced mild hypotensive episodes immediately following injection, but they recovered uneventfully. Butorphanol was shown to be a safe and effective agent for dental premedication in this difficult patient population.

AB - Seventy institutionalized severely and profoundly retarded patients were administered intramuscular butorphanol, 1.0 to 4.0 mg, for premedication prior to dental procedures. These patients had been refractory to previous combined chloral hydrate and diphenhydramine treatment. Clinical efficacy was categorized according to the extent that adjunctive restraints were required to accomplish the dental procedure. A total of 151 butorphanol trials were recorded. Butorphanol was observed to be clinically effective in 74.8% of the administrations and sedation was observed in 28.2% of the trials. Dosage titration increased efficacy to 85.0%. Contribution of concurrent central nervous system depressant medication to clinical efficacy and dose requirements lacked statistical significance; however, a strong trend (p = 0.068) was found in the medication-free group with higher dosage. Vomiting (2.6%) was the most frequent adverse effect observed. One patient had marked cardiorespiratory depression that was promptly reversed by intravenous naloxone. Two patients experienced mild hypotensive episodes immediately following injection, but they recovered uneventfully. Butorphanol was shown to be a safe and effective agent for dental premedication in this difficult patient population.

UR - http://www.scopus.com/inward/record.url?scp=0023133311&partnerID=8YFLogxK

U2 - 10.1016/0030-4220(87)90248-9

DO - 10.1016/0030-4220(87)90248-9

M3 - Article

C2 - 2952929

AN - SCOPUS:0023133311

VL - 63

SP - 403

EP - 407

JO - Oral Surgery, Oral Medicine, Oral Pathology

JF - Oral Surgery, Oral Medicine, Oral Pathology

SN - 0030-4220

IS - 4

ER -